WO1999043651A3 - Inhibitors of phospholipase enzymes - Google Patents

Inhibitors of phospholipase enzymes Download PDF

Info

Publication number
WO1999043651A3
WO1999043651A3 PCT/US1999/003899 US9903899W WO9943651A3 WO 1999043651 A3 WO1999043651 A3 WO 1999043651A3 US 9903899 W US9903899 W US 9903899W WO 9943651 A3 WO9943651 A3 WO 9943651A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
phospholipase enzymes
phospholipase
disclosed
enzymes
Prior art date
Application number
PCT/US1999/003899
Other languages
French (fr)
Other versions
WO1999043651A2 (en
Inventor
Jasbir S Seehra
Neelu Kaila
John C Mckew
Frank Lovering
Jean E Bemis
Yibin Xiang
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK1274-2000A priority Critical patent/SK12742000A3/en
Priority to IL13771899A priority patent/IL137718A0/en
Application filed by Genetics Inst filed Critical Genetics Inst
Priority to AU27826/99A priority patent/AU2782699A/en
Priority to EEP200000486A priority patent/EE200000486A/en
Priority to CA002322161A priority patent/CA2322161A1/en
Priority to KR1020007009456A priority patent/KR20010041343A/en
Priority to JP2000533409A priority patent/JP2002504539A/en
Priority to EP99908379A priority patent/EP1056719A2/en
Priority to BR9908280-2A priority patent/BR9908280A/en
Priority to HU0100757A priority patent/HUP0100757A3/en
Priority to EA200000868A priority patent/EA200000868A1/en
Publication of WO1999043651A2 publication Critical patent/WO1999043651A2/en
Publication of WO1999043651A3 publication Critical patent/WO1999043651A3/en
Priority to NO20004220A priority patent/NO20004220L/en
Priority to HR20000552A priority patent/HRP20000552A2/en
Priority to BG104780A priority patent/BG104780A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Novel compounds are disclosed which inhibit the activity of phospholipase enzymes, particularly cytosolic phospholipase A2. Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.
PCT/US1999/003899 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes WO1999043651A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
BR9908280-2A BR9908280A (en) 1998-02-25 1999-02-24 Phospholipase enzyme inhibitors
EP99908379A EP1056719A2 (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes
AU27826/99A AU2782699A (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes
IL13771899A IL137718A0 (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes
CA002322161A CA2322161A1 (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes
KR1020007009456A KR20010041343A (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes
HU0100757A HUP0100757A3 (en) 1998-02-25 1999-02-24 Indole derivatives as inhibitors of phospholipase enzymes and pharmaceutical compositions containing them
SK1274-2000A SK12742000A3 (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes
EEP200000486A EE200000486A (en) 1998-02-25 1999-02-24 Phospholipase enzyme inhibitors, a pharmaceutical composition containing them, and a method of treating an inflammatory response in a mammal.
JP2000533409A JP2002504539A (en) 1998-02-25 1999-02-24 Phospholipase enzyme inhibitors
EA200000868A EA200000868A1 (en) 1998-02-25 1999-02-24 PHOSPHOLIPAZ INHIBITORS
NO20004220A NO20004220L (en) 1998-02-25 2000-08-23 Inhibitors of phospholipase enzymes
HR20000552A HRP20000552A2 (en) 1998-02-25 2000-08-24 Inhibitors of phospholipase enzymes
BG104780A BG104780A (en) 1998-02-25 2000-09-19 Inhibitors of phospholipase enzymes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3006298A 1998-02-25 1998-02-25
US09/030,062 1998-02-25

Publications (2)

Publication Number Publication Date
WO1999043651A2 WO1999043651A2 (en) 1999-09-02
WO1999043651A3 true WO1999043651A3 (en) 1999-12-16

Family

ID=21852314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003899 WO1999043651A2 (en) 1998-02-25 1999-02-24 Inhibitors of phospholipase enzymes

Country Status (19)

Country Link
EP (1) EP1056719A2 (en)
JP (1) JP2002504539A (en)
KR (1) KR20010041343A (en)
CN (1) CN1299347A (en)
AU (1) AU2782699A (en)
BG (1) BG104780A (en)
BR (1) BR9908280A (en)
CA (1) CA2322161A1 (en)
EA (1) EA200000868A1 (en)
EE (1) EE200000486A (en)
HR (1) HRP20000552A2 (en)
HU (1) HUP0100757A3 (en)
ID (1) ID27280A (en)
IL (1) IL137718A0 (en)
NO (1) NO20004220L (en)
PL (1) PL342995A1 (en)
SK (1) SK12742000A3 (en)
TR (1) TR200002446T2 (en)
WO (1) WO1999043651A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841295B2 (en) 2005-11-04 2014-09-23 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8940752B2 (en) 2009-06-29 2015-01-27 Incyte Corporation Pyrimidinones as PI3K inhibitors
US9096600B2 (en) 2010-12-20 2015-08-04 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US9199982B2 (en) 2011-09-02 2015-12-01 Incyte Holdings Corporation Heterocyclylamines as PI3K inhibitors
US9309251B2 (en) 2012-04-02 2016-04-12 Incyte Holdings Corporation Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
US9403847B2 (en) 2009-12-18 2016-08-02 Incyte Holdings Corporation Substituted heteroaryl fused derivatives as P13K inhibitors

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE263162T1 (en) * 1999-05-05 2004-04-15 Aventis Pharma Ltd UREA DERIVATIVES AND THEIR USE AS CELL ADHESION MODULATORS
DE60128475T2 (en) 2000-07-25 2008-02-07 Merck & Co., Inc. N-SUBSTITUTED INDOLE USED IN THE TREATMENT OF DIABETES
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
US6916850B2 (en) 2001-05-03 2005-07-12 Galileo Pharmaceuticals, Inc. Pyruvate derivatives
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7291639B2 (en) 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
PT1397130E (en) 2001-06-20 2007-11-13 Wyeth Corp Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003000668A1 (en) * 2001-06-25 2003-01-03 Nippon Soda Co., Ltd. Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US6984735B2 (en) 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US6635771B2 (en) 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US7101875B2 (en) 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
DK1892239T3 (en) * 2001-12-03 2013-03-25 Wyeth Llc Inhibitors of cytosol phospholipase A2
SI1451154T1 (en) * 2001-12-03 2008-06-30 Wyeth Corp Inhibitors of cytosolic phospholipase a2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
US7186746B2 (en) 2002-08-29 2007-03-06 Merck & Co., Inc. Indoles having anti-diabetic activity
JP4340232B2 (en) 2002-08-29 2009-10-07 メルク エンド カムパニー インコーポレーテッド Indoles having anti-diabetic activity
DE60332769D1 (en) 2002-11-07 2010-07-08 Organon Nv INDOLE FOR TREATING DISEASES RELATED TO THE ANDROGEN RECEPTOR
CN1726190A (en) 2002-12-10 2006-01-25 惠氏公司 Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
MXPA05006282A (en) 2002-12-10 2005-08-19 Wyeth Corp Substituted 3-alkyl and 3-arylalkyl 1h.
AU2003296324A1 (en) 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
BR0316584A (en) 2002-12-10 2005-10-04 Wyeth Corp Substituted oxo-acetyl amino indole acetic acid derivatives as plasminogen activator inhibitor-1 inhibitors (parent-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
TW200510305A (en) * 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
WO2005123673A1 (en) 2004-06-18 2005-12-29 Biolipox Ab Indoles useful in the treatment of inflammation
CN101039936A (en) 2004-08-23 2007-09-19 惠氏公司 Oxazolo-naphthyl acids as plasminogen activator inhibitor type-1(pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
WO2006045478A1 (en) * 2004-10-27 2006-05-04 F. Hoffmann-La Roche Ag New indole or benzimidazole derivatives
EP1841735B1 (en) * 2005-01-19 2011-03-09 Biolipox AB Indoles useful in the treatment of inflammation
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
GT200600228A (en) * 2005-05-27 2006-12-26 INHIBITORS OF PHOSPHOLIPASE A2 CITOSOLICA
AU2006279496A1 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
EP2240444A1 (en) 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
AR072297A1 (en) 2008-06-27 2010-08-18 Novartis Ag DERIVATIVES OF INDOL-2-IL-PIRIDIN-3-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE SYNTHESIS ALDOSTERONE.
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
PT2875013T (en) 2012-07-17 2018-02-28 Glaxosmithkline Ip No 2 Ltd Indolecarbonitriles as selective androgen receptor modulators
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016138363A1 (en) 2015-02-27 2016-09-01 Incyte Corporation Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
EP3860998B1 (en) 2018-10-05 2023-12-27 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1492929A (en) * 1966-05-11 1967-08-25 Roussel Uclaf Novel substituted 1- (omega-carboxyalkyl) indoles and method of preparation
CH484111A (en) * 1966-04-12 1970-01-15 Sumitomo Chemical Co Process for preparing new derivatives of N-benzoyl-3-indolylic aliphatic acid
US3505354A (en) * 1967-05-18 1970-04-07 Geigy Chem Corp 2-methyl-3-p-halobenzoylindole-n-aliphatic acids
DE1816335A1 (en) * 1968-12-21 1970-07-09 Thiemann Gmbh Chem Pharm Fabri 2-methyl-5-alkoxy-3-acyl-indole-1-acetic - acid and esters thereof
EP0337767A1 (en) * 1988-04-13 1989-10-18 Ici Americas Inc. Cyclic amides
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
WO1993023391A1 (en) * 1992-05-13 1993-11-25 Syntex (U.S.A.) Inc. Substituted indoles and azaindoles as angiotensin ii antagonists
US5290798A (en) * 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
EP0620215A1 (en) * 1993-04-16 1994-10-19 Eli Lilly And Company 1H-indole-3-acetamide derivatives as sPLA2 inhibitors
WO1995013266A1 (en) * 1993-11-12 1995-05-18 Merckle Gmbh Chem.-Pharm. Fabrik Acylpyrrole-alkanoic acids and indole-2-alkanoic acids plus their derivatives for use as inhibitors of phospholipase a¿2?
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
WO1998005637A1 (en) * 1996-08-01 1998-02-12 Merckle Gmbh Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a¿2?
WO1998008818A1 (en) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH484111A (en) * 1966-04-12 1970-01-15 Sumitomo Chemical Co Process for preparing new derivatives of N-benzoyl-3-indolylic aliphatic acid
FR1492929A (en) * 1966-05-11 1967-08-25 Roussel Uclaf Novel substituted 1- (omega-carboxyalkyl) indoles and method of preparation
US3505354A (en) * 1967-05-18 1970-04-07 Geigy Chem Corp 2-methyl-3-p-halobenzoylindole-n-aliphatic acids
DE1816335A1 (en) * 1968-12-21 1970-07-09 Thiemann Gmbh Chem Pharm Fabri 2-methyl-5-alkoxy-3-acyl-indole-1-acetic - acid and esters thereof
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
EP0337767A1 (en) * 1988-04-13 1989-10-18 Ici Americas Inc. Cyclic amides
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5290798A (en) * 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
WO1993023391A1 (en) * 1992-05-13 1993-11-25 Syntex (U.S.A.) Inc. Substituted indoles and azaindoles as angiotensin ii antagonists
EP0620215A1 (en) * 1993-04-16 1994-10-19 Eli Lilly And Company 1H-indole-3-acetamide derivatives as sPLA2 inhibitors
WO1995013266A1 (en) * 1993-11-12 1995-05-18 Merckle Gmbh Chem.-Pharm. Fabrik Acylpyrrole-alkanoic acids and indole-2-alkanoic acids plus their derivatives for use as inhibitors of phospholipase a¿2?
WO1998005637A1 (en) * 1996-08-01 1998-02-12 Merckle Gmbh Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a¿2?
WO1998008818A1 (en) * 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. ROY ET AL., IND. J. PHYSIOL. PHARMAC., vol. 26, no. 3, 1982, pages 207 - 214, XP002118794 *
DILLARD R D ET AL: "INDOLE INHIBITORS OF HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE A2. 2. INDOLE-3-ACETAMIDES WITH ADDITIONAL FUNCTIONALITY", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 26, 20 December 1996 (1996-12-20), pages 5137 - 5158, XP002046055, ISSN: 0022-2623 *
DILLARD R D ET AL: "INDOLE INHIBITORS OF HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE A21. INDOLE-3-ACETAMIDES", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 26, 20 December 1996 (1996-12-20), pages 5119 - 5136, XP002046054, ISSN: 0022-2623 *
DRAHEIM S E ET AL: "INDOLE INHIBITORS OF HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE A2. 3. INDOLE-3-GLYOXAMIDES", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 26, 1 January 1996 (1996-01-01), pages 5159 - 5175, XP002073103, ISSN: 0022-2623 *
K.J. DOEBEL ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 15, no. 10, 1972, WASHINGTON US, pages 1081 - 1082, XP002118793 *
SCHEVITZ R W ET AL: "STRUCTURE-BASED DESIGN OF THE FIRST POTENT AND SELECTIVE INHIBITOR OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2", NATURE STRUCTURAL BIOLOGY, vol. 2, no. 6, 1 June 1995 (1995-06-01), pages 458 - 465, XP002046508, ISSN: 1072-8368 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841295B2 (en) 2005-11-04 2014-09-23 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8940752B2 (en) 2009-06-29 2015-01-27 Incyte Corporation Pyrimidinones as PI3K inhibitors
US9434746B2 (en) 2009-06-29 2016-09-06 Incyte Corporation Pyrimidinones as PI3K inhibitors
US9403847B2 (en) 2009-12-18 2016-08-02 Incyte Holdings Corporation Substituted heteroaryl fused derivatives as P13K inhibitors
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US9096600B2 (en) 2010-12-20 2015-08-04 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9527848B2 (en) 2010-12-20 2016-12-27 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
US9199982B2 (en) 2011-09-02 2015-12-01 Incyte Holdings Corporation Heterocyclylamines as PI3K inhibitors
US9309251B2 (en) 2012-04-02 2016-04-12 Incyte Holdings Corporation Bicyclic azaheterocyclobenzylamines as PI3K inhibitors

Also Published As

Publication number Publication date
ID27280A (en) 2001-03-22
KR20010041343A (en) 2001-05-15
HUP0100757A3 (en) 2001-11-28
BR9908280A (en) 2000-10-31
EA200000868A1 (en) 2001-04-23
NO20004220L (en) 2000-10-05
IL137718A0 (en) 2001-10-31
AU2782699A (en) 1999-09-15
EE200000486A (en) 2002-02-15
SK12742000A3 (en) 2001-05-10
PL342995A1 (en) 2001-07-16
CN1299347A (en) 2001-06-13
EP1056719A2 (en) 2000-12-06
NO20004220D0 (en) 2000-08-23
CA2322161A1 (en) 1999-09-02
TR200002446T2 (en) 2000-12-21
JP2002504539A (en) 2002-02-12
HUP0100757A1 (en) 2001-08-28
BG104780A (en) 2001-10-31
HRP20000552A2 (en) 2001-04-30
WO1999043651A2 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
AU3665199A (en) Inhibitors of impdh enzyme
EE200000522A (en) Phospholipase A2 Enzyme Inhibitor, a Pharmaceutical Composition Containing It and a Method for Inhibiting the Phospholipase Enzyme Activity
ZA973397B (en) Inhibitors of IMPDH enzyme.
DK0966465T3 (en) Inhibitors of IMPDH enzymes
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
WO2003006652A3 (en) Inhibition of specific histone deacetylase isoforms
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
CA2367017A1 (en) Inhibitors of impdh enzyme
AU2001228309A1 (en) N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
AP9901478A0 (en) Compounds for the treatment of ischemia.
AU6328094A (en) Saccharin derivative proteolytic enzyme inhibitors
WO1999005096A3 (en) Urokinase inhibitors
CA2257010A1 (en) Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia
ZA991975B (en) Enzyme inhibitors.
WO2000043373A3 (en) Kinase inhibitors
WO2003048122A3 (en) Inhibitors of cytosolic phospholipase a2
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
CA2284142A1 (en) Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
EP0983243A4 (en) Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain
AU7961498A (en) 9a-azalides, compositions containing such compounds and methods of treatment
ZA988025B (en) Method for enhancing the activity of an enzyme.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99805385.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 137718

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1200000702

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 506330

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1999908379

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 27826/99

Country of ref document: AU

Ref document number: 2000/02446

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 12742000

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2322161

Country of ref document: CA

Ref document number: 2322161

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20000552A

Country of ref document: HR

Ref document number: PA/a/2000/008295

Country of ref document: MX

Ref document number: IN/PCT/2000/253/KOL

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2000 533409

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020007009456

Country of ref document: KR

Ref document number: PV2000-3113

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 200000868

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1999908379

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007009456

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2000-3113

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020007009456

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2000-3113

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999908379

Country of ref document: EP